FDA Inspection 1232759 — Vanda Pharmaceuticals Inc
The FDA completed an inspection of Vanda Pharmaceuticals Inc on March 12, 2024 in Washington, DC. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). 2 citations were issued during this inspection. Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 12, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Washington, DC (United States)
Additional Details
Sponsor, Contract Research Organization
Citations
| ID | CFR | Description |
|---|---|---|
| 7388 | 21 CFR 50.25(a)(2) | Reasonably foreseeable risks or discomforts |
| 7557 | 21 CFR 312.56(b) | Notification of FDA of termination of investigator |